GuruFocus - On June 14, 2024, Jon Congleton, CEO of Mineralys Therapeutics Inc (NASDAQ:MLYS), executed a sale of 72,797 shares of the company, according to the SEC Filing. Following this transaction, the insider now owns 976,271 shares of the company.
Mineralys Therapeutics Inc (NASDAQ:MLYS) is focused on developing targeted therapies for cardiovascular and kidney diseases. The company's approach aims to address the underlying causes of these conditions with precision medicine.
The shares were sold at a price of $12.7 each, placing the market cap of the company at approximately $624.579 million. This transaction follows a pattern observed over the past year where Jon Congleton has sold a total of 72,797 shares and purchased 10,750 shares.
The insider transaction history at Mineralys Therapeutics Inc (NASDAQ:MLYS) shows a balance of insider activities over the past year, with 5 insider buys and 4 insider sells. This recent sale by the insider might be of interest to investors keeping track of insider trends.
Valuation metrics such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow are essential for assessing the stock's current valuation. Investors might also consider the GF Value to determine if the stock is trading at a fair value.
This insider sell event is a part of the ongoing financial activities within Mineralys Therapeutics Inc (NASDAQ:MLYS) that stakeholders may want to consider as part of their investment decision-making process.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This content was originally published on Gurufocus.com
